Affrime M B, Blecker D L, Lyons P J, Pitone J M, Swartz C D, Lowenthal D T
J Dial. 1979;3(2-3):207-18. doi: 10.3109/08860227909063941.
The in vitro plasma protein binding was determined in nine maintenance hemodialysis patients who later underwent renal transplantation. The organic acid fluorescein (10 micrograms/ml) or the organic base quinidine (5 micrograms/ml) was added to the pre and post transplant serum of these patients. Drug concentrations were measured spectrophotofluorometrically after equilibrium dialysis. The results were compared with the plasma protein binding of eight normal volunteers. The patients on maintenance hemodialysis had lower plasma protein binding of fluorescein than normals (78 +/- 5% vs 89 +/- 4, p less than 0.001). Plasma protein binding improved significantly after renal transplantation (85 +/- 3, p less than 0.01) but was still lower than in normals (p 0.05). Plasma protein binding of quinidine was not significantly different than in normal volunteers (77 +/- 8%) either prior to (72 +/- 10%) or after (73 +/- 12%) kidney transplantation. Plasma protein binding of quinidine remains unaffected by renal transplantation. However, the abnormal plasma protein binding or organic acids in chronic renal failure may be significantly improved by renal transplantation.
对9名维持性血液透析患者进行了体外血浆蛋白结合率测定,这些患者随后接受了肾移植。向这些患者移植前后的血清中加入有机酸荧光素(10微克/毫升)或有机碱奎尼丁(5微克/毫升)。平衡透析后,采用分光荧光法测定药物浓度。将结果与8名正常志愿者的血浆蛋白结合率进行比较。维持性血液透析患者荧光素的血浆蛋白结合率低于正常人(78±5%对89±4,p<0.001)。肾移植后血浆蛋白结合率显著改善(85±3,p<0.01),但仍低于正常人(p<0.05)。奎尼丁的血浆蛋白结合率在肾移植前(72±10%)和肾移植后(73±12%)与正常志愿者相比均无显著差异(77±8%)。肾移植不影响奎尼丁的血浆蛋白结合率。然而,肾移植可显著改善慢性肾衰竭患者异常的血浆蛋白结合或有机酸情况。